Capital Partners – Talk Bio

bluebird bio Rebrands as Genetix Biotherapeutics Following Private Equity Buyout

1 month ago talkbio0Tagged Anemia, Sickle Cell, Bluebird Bio, Capital Partners, Carlyle, Cerebral Adrenoleukodystrophy, commercial, David Meek, DKK1 gene, execution, FDA-approved therapies, gene therapy, Genetix Biotherapeutics, Investments, Manufacturing, Private Equity, rebranding, Thalassemia

bluebird bio; Genetix Biotherapeutics; private equity buyout; Carlyle; SK Capital Partners; gene therapy; rebranding; FDA-approved therapies; David Meek; sickle cell disease; β-thalassemia; cerebral adrenoleukodystrophy; commercial execution; manufacturing investment

Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout

8 months ago talkbio0Tagged Acelyrin, Capital Partners, Concentra Biosciences, Contraceptives, Oral, Pliant, Poisons, Tang

Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Private Equity Deal

12 months ago talkbio0Tagged Avid, Biological Factors, Bioservices, Capital Partners, CDMO, GHO, Private Equity

Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, biologics CDMO, private equity acquisition, $1.1 billion deal

Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million

1 year ago talkbio0Tagged Capital Partners, central venous catheter (CVC) sets, Extracorporeal, Healthcare services, Immunotherapy, Lymphoma, T-Cell, Cutaneous, mallinckrodt, medical technology, Photopheresis, RNASE3 gene, Therakos

Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services